AzTrials
AzTrials

DiabetesNCT03095196

Multipolar CRT-d and Diabetes

An observational study of Diabetes and Heart Failure, run by Celestino Sardu.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Type 2 Diabetes Mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart (HF) patients treated by Cardiac Resynchronization Therapy with a defibrillator (CRT-d). Methods: One hundred and ninety five T2DM patients will receive a CRT-d treatment. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Multipolar CRT-d, plus conventional drug therapy for HF., Bipolar CRT-d, plus conventional drug therapy for HF. and HF drugs
Type of treatment
Medical device
How many people
190 participants
Where
No sites listed yet
Study dates
1 Sep 2012to 1 Sep 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 213 consecutive T2DM patients with stable chronic heart failure, New York Heart Association (NYHA) functional class II or III, left bundle branch block, severe left ventricle ejection fraction reduction (LVEF < 35%), stable sinus rhythm, candidates to receive a CRT-d treatment according to the international guidelines. Exclusion criteria were as follows: age <18 or >75 years, ejection fraction >35%, previous implantable cardioverter defibrillator (ICD), CRT-d and/or pacemaker implant, absence of informed patient consent, and any condition that would make survival for 1 year unlikely.

Who may be able to join

  • T2DM patients with stable chronic heart failure, New York Heart Association (NYHA) functional class II or III, left bundle branch block, severe left ventricle ejection fraction reduction (LVEF < 35%), stable sinus rhythm, candidates to receive a CRT-d treatment

Who cannot join

  • age <18 or >75 years, ejection fraction >35%, previous implantable cardioverter defibrillator (ICD), CRT-d and/or pacemaker implant, absence of informed patient consent, and any condition that would make survival for 1 year unlikely.

About this study

Official title: Multipolar Pacing by Cardiac Resynchronization Therapy With a Defibrillator as Treatment in Type 2 Diabetes Mellitus Failing Heart Patients: Impact on Responders Rate, and Clinical Outcomes.

Background: Type 2 Diabetes Mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart (HF) patients treated by Cardiac Resynchronization Therapy with a defibrillator (CRT-d).

Methods: One hundred and ninety five T2DM patients will receive a CRT-d treatment. Randomly the study population will receive a CRT-d via multipolar left ventricle (LV) lead pacing (n 99 as Multipolar group), v/s a CRT-d via bipolar LV pacing (n 96, as Bipolar group). These patients will be followed by clinical, and instrumental assessment, and telemetric device control at follow up. Study design will be to evaluate, in failing heart T2DM patients, cardiac deaths, all cause deaths, arrhythmic events, CRT-d responders rate, hospitalizations for HF worsening, phrenic nerve stimulation (PNS), and LV catheter dislodgment events (and re-intervention for LV catheter re-positioning), comparing multipolar CRT-d v/s bipolar CRT-d group of patients at follow up.

Read the detailed description

Introduction: Type 2 diabetes mellitus (T2DM) is a worldwide increasing disease, impacting on heart functions, and cardiac diseases, and outcomes. T2DM may lead to heart failure (HF) disease, and conditioning HF disease progression, and the response to treatments. In HF patients, cardiac resynchronization therapy with a defibrillator (CRT-d) is a well-established treatment to improve symptoms, quality of life, NYHA class, and clinical outcomes. T2DM may condition the CRT-d response. The advancement of CRT-d technology worked to reduce implant complications, phrenic nerve stimulation (PNS) events, and left ventricle (LV) catheter dislodgments, and to ameliorate the CRT-d responders rate, and clinical outcomes. The multipolar LV lead pacing represented one of the waited technological advancement in CRT-d technology, resulted in a stable and continuous CRT-d pacing. The stable and continuous CRT-d pacing may condition the prognosis, and CRT-d responders rate in failing heart patients. At our knowledge, there are not data investigating these effects in a population of T2DM failing heart subjects. In this study T2DM failing heart patients randomly received a CRT-d via multipolar LV lead and/or a CRT-d via bipolar LV lead. In these patients we evaluated, as primary study endpoints, PNS events, LV lead dislodgments, interventions for LV re-positioning, cardiac deaths, all cause deaths, stroke events, and hospitalizations for HF worsening. As secondary endpoints we evaluated arrhythmic events, strokes, and CRT-d responders rate. Our study hypothesis was that, in T2DM failing heart patients multipolar LV pacing may lead to a reduction of PNS episodes, LV leads dislodgments, and interventions to re-positioning LV leads, leading to a significant amelioration of the HF clinical status, and of the CRT-d responders rate. These effects induced by multipolar CRT-d pacing may reduce arrhythmic events, hospitalizations for HF worsening, and of cardiac deaths, and all cause deaths in T2DM patients.

Methods: From September 2012 to September 2015 we conducted a multicenter, prospective, randomized study at University of Campania Luigi Vanvitelli, Italy, Catholic University of Sacred Heart, Campobasso, Italy, and John Paul II Research and Care Foundation, Campobasso, Italy. We screened 213 consecutive T2DM patients with stable chronic HF, NYHA functional class II or III, left bundle branch block, severe left ventricle ejection fraction reduction (LVEF < 35%), stable sinus rhythm, candidates to receive a CRT-d treatment according to the international guidelines. Exclusion criteria were: age <18 or >75 years, ejection fraction >35%, previous implantable cardioverter defibrillator (ICD), CRT-d and/or pacemaker implant, absence of informed patient consent, and any condition that would make survival for 1 year unlikely. 198 eligible patients were included in the study, and received a CRT-d treatment, and a traditional CRT-d ambulatory monitoring. The CRT-d has randomly undergone via multipolar left lead pacing (n 101) v/s bipolar left lead pacing (n 98). Study population was divided in Multipolar CRT-d group (multipolar LV pacing), v/s Bipolar CRT-d group (bipolar LV pacing), according to the LV lead stimulation catheter used, and implanted at enrolment. 99 patients in Multipolar CRT group v/s 96 patients in the Bipolar CRT group completed the follow up. All patients were informed about the study nature, and gave their written informed, and signed consent to participate in the study.

Study protocol: 199 patients received a CRT-d, then divided in multipolar CRT-d patients (n 101), and bipolar CRT-d patients (n 98). Before interventions, baseline laboratory studies, including HbA1c, lipid panel, and fibrinogen, were determined. Follow-up was concluded at 12 months after CRT-d implant. Responders patients to a CRT-d treatment were defined by evidence of LV reverse remodeling, 6 minutes-walk improvement and Minnesota Living with Heart Failure scale improvement. Enrolled patients were followed by clinical, instrumental assessment, and device telemetric control at follow up. During these visits we reported lead functionality parameters, and arrhythmic events in CRT-d recipients, PNS episodes, and CRT-d effect on clinical outcomes. This study was conducted from September 2012 to December 2015. The study was conducted in accordance with the Declaration of Helsinki. The Ethics Committees of all participating institutions approved the protocol.

Intervention phase: CRT-d implant procedure, and LV pacing leads positioning Experienced electrophysiologists performed CRT implant procedures, that were standardized. Right atrial catheters were all placed in right atrial appendage, right ventricular catheters in right ventricle apex, as indicated by antero-posterior, right anterior, and left anterior oblique views projections at radioscopic imaging. LV epicardial catheters were placed by percutaneous coronary sinus catheterization. In this case we have chosen, by previous described radioscopic projections and angiography, a lateral and/or posterior-lateral target vessel, according to international guidelines recommendations. We randomly chose a multipolar and/or a bipolar left ventricle pacing lead, as described before in the text. Implantation duration was defined as the time between skin incision until suture. Measurements were repeated within 24hours of implantation using the implanted pulse generator and pacemaker programmer, and then 10th days, 6th month, 12th month after discharge at follow up. The sensing and pacing LV configurations were defined by 10 bipolar configurations for multipolar LV pacing modality, and at least 4 different left ventricle pacing configurations (LV tip to either LV ring or right ventricular (RV) coil, and LV ring to either LV tip or RV coil) for the bipolar left ventricle pacing group. LV pacing leads were connected to an appropriate bipolar CRT-D device.

Follow up phase:

Lead functionality parameters Right atrium, right ventricle, and left ventricle leads functionality parameters were measured, as P, and R-wave amplitude values (sensing thresholds), lead impedances values (impedance thresholds), and lead pacing outputs values (pacing thresholds). The sensing thresholds values were obtained from the intra-cardiac electrograms records, measured using a sensing configuration. The pacing thresholds, and impedance thresholds values, were measured using pacing catheter configurations. To measure intra thoracic impedance (Ohm), and pacing thresholds (Volt for milliseconds), we focused on the right ventricle (RV) coil electrode to device case pathway configuration, and on the left ventricle (LV) tip to LV ring configuration. These parameters were evaluated during ambulatory follow up visits, and device interrogations at follow up.

Arrhythmic events in CRT-d recipients Arrhythmic events were defined as atrial fibrillation (AF), ventricular tachycardia (VT), and ventricular fibrillation (VF) episodes, and implantable cardioverter defibrillator (ICD) shocks. AF was defined as paroxysmal, and/or not paroxysmal according to authors suggestions. VT was defined as arrhythmia originating from ventricular chambers, sustained and/or not sustained by arrhythmic event duration. VF was defined as a fibrillating arrhythmia originating from ventricular chambers, and associated to hemodynamic instability, and cardiac arrest. By CRT-d devices interrogations at follow up we reported ICDs shocks for each CRT-d patient, at 10th days, 6th month, and at 12th month after implantation.

Phrenic nerve stimulation events PNS and left ventricle pacing leads threshold were measured by a standard protocol at CRT-d implant, and during all follow up durations by CRT-d devices interrogations. In case of PNS diagnosis during follow up, by patients symptoms assessment, devices interrogations, and physician ambulatory diagnosis, we reached the best left ventricle lead pacing configuration to solve PNS.

LV leads dislodgments LV catheter dislodgments resulted by the movement of the catheter into and out of the coronary sinus implantation vessel site, and then causing a change in the catheter tip location. It was diagnosed by patients clinical symptoms, hospital admissions schedules, hospital discharge schedules, and during medical interrogation at follow up visits, and was confirmed by radiographic biplane projections assessment.

CRT-d effect on clinical outcomes CRT-d responders rate was evaluated by periodic clinical examination, and echocardiography assessment. Interventions for LV lead re-positioning were defined as interventions done after the first CRT-d implant, and were evaluated by hospital admissions schedules, hospital discharge schedules, and medical interrogation at follow up visits. These interventions were done in case of LV catheter dislodgments. Hospitalization rate was reported during telephonic interviews, by hospital admissions schedules, hospital discharge schedules, and during medical interrogation at follow up visits. Cardiac deaths, all cause of deaths, and stroke events were evaluated during office follow up visits 10 days after clinical discharge, and after 6th and 12th months by the treating physician, by telephonic interview, hospital admission, and discharge schedules. At each clinical follow-up, right atrial, right ventricular, and left ventricular leads functionality, atrial, and ventricular arrhythmias, ICD shocks, and biventricular pacing percentage, were evaluated and reported for each patient. NYHA classification was re-assessed, and patients graded their overall condition as unchanged or slightly, moderately, or markedly worsened, or improved since randomization by global self-assessment. All patients were instructed to report about devices alarms, loss of lead capture, phrenic nerve stimulation, and arrhythmias. All patients were instructed regularly to assess body weight, occurrence of dyspnea, and any clinical symptom. At each visit patients were asked whether medical events or symptoms suggestive of cardiac arrhythmias occurred, and an ECG, and an ECG Holter monitoring, were both performed to detect the presence of asymptomatic arrhythmias. Clinical evaluations included physical examination, vital signs, and review of adverse events.

Study endpoints As primary endpoints we monitored CRT-d effect in multipolar CRT-d patients v/s bipolar CRT-d patients in terms of PNS, LV leads dislodgments, interventions to re-position LV leads, hospitalization rate for HF worsening, cardiac deaths, and all cause deaths. As secondary endpoints we monitored CRT-d responders rate, arrhythmic events, and strokes in both groups (multipolar CRT-d v/s bipolar CRT-d patients).

Statistical methods A qualified statistician analyzed all collected data. The patients were divided before in multipolar CRT-d group v/s bipolar CRT-d group, and during follow up visits, and controls in CRT-d responders v/s CRT-d non-responders. Continuous variables were expressed as means and standard deviations, and were tested by two-tailed Student t test for paired or unpaired data, as appropriate, or by one-way analysis of variance (ANOVA) for more than two independent groups of data. The categorical variables were compared by chi-square or Fisher exact test where appropriate. Survival analysis was performed with the use of the Kaplan-Meier method. Predictors of the study endpoints were evaluated by using Cox regression models in which covariates for the adjustment were selected if associated with a p value ≤0.25 at univariate analysis. A stepwise method with backward elimination was used and hazard ratios (HR) with 95% confidence intervals (CI) were derived. We considered a two-sided p value of less than 0.05 as statistically significant. The statistical analysis was performed using the SPSS software package for Windows 17.0 (SPSS Inc., Chicago Illinois).

Being tested
Multipolar CRT-d, plus conventional drug therapy for HF., Bipolar CRT-d, plus conventional drug therapy for HF., HF drugs
Medical subject headings
Diabetes Mellitus, Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multipolar CRT-d, plus conventional drug therapy for HF.Device

    A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.

  • Bipolar CRT-d, plus conventional drug therapy for HF.Device

    A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.

  • HF drugsDrug

    full medical therapy to treat HF symptoms and its progression.

Study groups in NCT03095196
Study groupRoleWhat they receive
T2DM, treated by multipolar CRT-dType 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
Receives: Device: Multipolar CRT-d, plus conventional drug therapy for HF.; Drug: HF drugs
T2DM, treated by bipolar CRT-dType 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
Receives: Device: Bipolar CRT-d, plus conventional drug therapy for HF.; Drug: HF drugs

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phrenic nerve stimulation episodes

    As primary endpoints we monitored CRT-d effect in multipolar CRT-d patients v/s bipolar CRT-d in terms of Phrenic nerve stimulation episodes (PNS). PNS were assessed by left ventricle pacing leads threshold by a standard protocol at CRT-d implant, and during all follow up durations by CRT-d devices interrogations. In case of PNS diagnosis during follow up, by patients symptoms assessment (phrenic simulations during CRTd pacing), and confirmed by devices interrogations, and physician ambulatory diagnosis, we reached the best left ventricle lead pacing configuration to solve PNS.

    Measured: 24 months

  2. Left Ventricle (LV) leads dislodgments

    As primary endpoints we monitored CRT-d effect in multipolar CRT-d patients v/s bipolar CRT-d in terms of LV leads dislodgments, as confirmed by the movement of the catheter into and out of the coronary sinus implantation vessel site, and then causing a change in the catheter tip location. It was diagnosed by patients clinical symptoms, hospital admissions schedules, hospital discharge schedules, and during medical interrogation at follow up visits, and was confirmed by radiographic biplane projections assessment.

    Measured: 24 months

  3. Interventions to re-position LV leads

    As primary endpoints we monitored CRT-d effect in multipolar CRT-d patients v/s bipolar CRT-d in terms of interventions done after the first CRT-d implant to re-position LV leads in case of LV leads dislodgments. This endpoint was evaluated by hospital admissions schedules, hospital discharge schedules, and medical interrogations at follow up visits. These interventions were done in case of LV catheter dislodgments.

    Measured: 24 months

  4. Hospitalization rate for HF worsening

    As primary endpoints we monitored CRT-d effect in multipolar CRT-d patients v/s bipolar CRT-d in terms of hospitalization rate for HF worsening. Hospitalization rate was reported during telephonic interviews, by hospital admissions schedules, hospital discharge schedules, and during medical interrogation at follow up visits.

    Measured: 24 months

  5. Cardiac deaths

    As primary endpoints we monitored CRT-d effect in multipolar CRT-d patients v/s bipolar CRT-d in terms of Cardiac deaths. Cardiac deaths were evaluated during office follow up visits 10 days after clinical discharge, and after 6th and 12th months by the treating physician, by telephonic interview, hospital admission, and discharge schedules.

    Measured: 24 months

  6. All cause deaths.

    As primary endpoints we monitored CRT-d effect in multipolar CRT-d patients v/s bipolar CRT-d in terms of all cause deaths. Alla cause deaths were evaluated during office follow up visits 10 days after clinical discharge, and after 6th and 12th months by the treating physician, by telephonic interview, hospital admission, and discharge schedules.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2017
  2. Study start1 Sep 2012
  3. Primary completion1 Sep 2014
  4. Study completion1 Sep 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
190 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03095196
Sponsor's protocol ID
JPS912.915
Status last verified
Apr 2017
First submitted
9 Mar 2017
Last updated
25 Apr 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Sardu C, Barbieri M, Santamaria M, Giordano V, Sacra C, Paolisso P, Spirito A, Marfella R, Paolisso G, Rizzo MR. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. Cardiovasc Diabetol. 2017 Jun 9;16(1):75. doi: 10.1186/s12933-017-0554-2.

    PubMed 28599667

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes and Heart Failure, run by Celestino Sardu.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phrenic nerve stimulation episodes (time frame: 24 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03095196, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in